Cellular immunity and immunotherapy of brain tumors.

@article{Prins2004CellularIA,
  title={Cellular immunity and immunotherapy of brain tumors.},
  author={Robert M. Prins and Linda M. Liau},
  journal={Frontiers in bioscience : a journal and virtual library},
  year={2004},
  volume={9},
  pages={
          3124-36
        }
}
  • R. Prins, L. Liau
  • Published 1 September 2004
  • Biology, Medicine
  • Frontiers in bioscience : a journal and virtual library
Factors influencing the host immune response to central nervous system (CNS) tumors are not yet well understood. This review will outline what is known about anti-tumor immune responses against CNS tumors and describe how advances in our knowledge of basic immunology may be applied to brain tumor immunotherapy. We will first focus on cellular immune system interactions involved in peripheral anti-tumor immune responses. Then, we will discuss characteristics of tumors arising within the confines… 

Figures and Tables from this paper

Immunotherapeutic approaches for glioma.
TLDR
This review of recent advances in the CNS and CNS tumor immunology addresses factors that may promote immune escape of gliomas and discusses novel immunotherapy strategies that have been recently tested in non-CNS tumors and show great potential for application to glioma.
Passive antibody-mediated immunotherapy for the treatment of malignant gliomas.
Current immunotherapeutic strategies for central nervous system tumors.
The role of regulatory T cells in malignant glioma.
TLDR
The role of Tregs in the immune suppression exhibited by malignant gliomas is focused on and potential therapeutic strategies related to Treg ablation are explored.
Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications
TLDR
An overview of currently available treatment options for malignant gliomas, existing gaps in knowledge of brain tumor immunology, and molecular techniques and targets that might be exploited for improved patient stratification and design of ‘custom immunotherapeutics’ are provided.
Immunotherapy for malignant glioma: current approaches and future directions
TLDR
General immunology of the central nervous system and the immunobiology of malignant glioma are reviewed to provide a foundation for understanding the rationale behind current gliomas immunotherapies.
Role of the systemic immune system in brain metastasis
Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain
TLDR
It is demonstrated that peripheral tolerance to endogenous TAA can be overcome to treat tumors in the brain and suggest a novel trafficking paradigm for the homing of tumor-specific T cells that target CNS tumors.
Anti-tumor activity and trafficking of self , tumor-specific T cells against tumors located in the brain , a , b
TLDR
It is demonstrated that peripheral tolerance to endogenous TAA can be overcome to treat tumors in the brain and suggest a novel trafficking paradigm for the homing of tumor-specific T cells that target CNS tumors.
NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain1
TLDR
Non-Ag-loaded, immature DC administration, in the setting of CD8 genetically deficient mice, can induce dramatic antitumor immune responses within the CNS that surpass the effects observed in wild-type mice.
...
...

References

SHOWING 1-10 OF 140 REFERENCES
Immune defects observed in patients with primary malignant brain tumors
T-cell immune responses in the brain and their relevance for cerebral malignancies
Immunology and Immunotherapy in Neurosurgical Disease
TLDR
Key aspects of recent insights into the cellular interactions involved in neuroimmunology are explored, which may suggest more rational approaches to the immunotherapy of neurosurgical disorders.
Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes.
TLDR
Results indicate for the first time that a reproducible and sustained eradication of a malignant glioma could be achieved by the adoptive transfer of tumor-sensitized, ex vivo expanded CTL.
Systemic T cell adoptive immunotherapy of malignant gliomas.
TLDR
Following T-cell transfer therapy, radiographic regression that lasted at least 6 months was demonstrated in two patients with recurrent tumors, and further trials are needed to determine whether this approach can provide therapeutic benefits and improve survival.
Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
TLDR
Evidence is provided that two common murine glioma cell lines (GL26 and GL261) express the melanoma antigens gp100 and tyrosinase-related protein 2 (TRP-2) that suggest that shared MAAs on gliomas can be targeted immunotherapeutically, pointing the way to a new potential treatment option for patients with malignantgliomas.
Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors
TLDR
Vaccination with bone marrow–generated DCs, pulsed with either B16 cell extract or B16 total RNA, can induce specific cytotoxic T lymphocytes against B16 tumor cells, and these data support the use of DC-based vaccines for the treatment of patients with CNS tumors.
Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination.
TLDR
The results demonstrate that the mechanisms of tumor immunity within the brain are different from those elicited against non-CNS tumors, and vaccination approaches exploiting the concept of epitope spreading may enhance the efficacy of antitumor immune responses within the immunologically privileged CNS.
Immune surveillance against a solid tumor fails because of immunological ignorance.
TLDR
Some antigenic peripheral sarcomas-and probably carcinomas-may grow not because they anergize or tolerize tumor-specific T cells, but because such tumors are immunologically dealt with as if they were in a so-called immunologically privileged site and are ignored for too long.
Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
TLDR
Sequential magnetic resonance image monitoring showed that the combinatory therapy consisting of intracerebral transplantation of IL-2-producing rat gliosarcoma 9L (9L/IL-2) cells and s.c. immunization of irradiated whole tumor cell vaccine is effective for recruiting activated T cells into the brain tumor site and could be a potential therapy for brain tumors.
...
...